Publications by authors named "Eleonora Toffoletti"

18Publications

Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.

Exp Hematol 2017 05 1;49:25-33. Epub 2017 Feb 1.

Division of Hematology and Stem Cell Transplantation, Azienda Sanitaria Universitaria Integrata di Udine, University of Udine, Udine UD, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2017.01.005DOI Listing
May 2017

BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.

Am J Hematol 2013 Oct 23;88(10):848-52. Epub 2013 Jul 23.

Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero-Universitaria Udine, Udine, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23516DOI Listing
October 2013

Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.

Ann Hematol 2012 Dec 15;91(12):1937-43. Epub 2012 Aug 15.

Division of Hematology and Bone Marrow Transplantation & Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, P.zzale S. M. Misericordia, 15, 33100 Udine, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-012-1551-x
Publisher Site
http://dx.doi.org/10.1007/s00277-012-1551-xDOI Listing
December 2012

Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.

Clin Transplant 2011 Mar-Apr;25(2):308-16

Division of Hematology and Bone Marrow Transplantation, Department of Medical and Morphologic Research, University of Udine, Udine, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1399-0012.2010.01251.xDOI Listing
August 2011

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.

Leuk Res 2008 Dec 14;32(12):1800-8. Epub 2008 Jul 14.

Division of Hematology, Bone Marrow Transplantation Unit, Department of Clinical and Morphological Research, University Hospital, Udine, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2008.05.011DOI Listing
December 2008